Reported results
- GAAP Net Income was $350 million and GAAP Diluted Earnings per Share was $2.10.
- Adjusted EBITDA was $1,032 million, up 8.7% year-over-year.
- Adjusted Diluted Earnings per Share was $3.34, up 11.3% year-over-year.
- Commercial Solutions revenue was $1,789 million, up 6.9% year-over-year.
- R&D Solutions revenue was $2,639 million, up 8.7% year-over-year.
- Free Cash Flow was $667 million.
Guidance
- Full-year 2026 revenue guidance between $17,350 million and $17,500 million.
- Full-year 2026 Adjusted EBITDA guidance between $4,025 million and $4,055 million.
- Full-year 2026 Adjusted Diluted Earnings per Share guidance between $12.90 and $13.00.
Notes
Effective January 1, 2026, the company implemented a new organizational model and recast prior period segment amounts. Additionally, a review of inactive trials resulted in an adjustment to backlog of approximately $2.1 billion.
Price and volatility reaction
The stock moved -0.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -11.8 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 273.6 | 2026-10-26 |
| Close after release | 271.55 | 2026-10-27 |
| Realised move | -0.8% | close to close |
| 30d ATM IV change | -11.8 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.
